Table 1 Predicted biological functions affected in GOT1 tumors after 177Lu-octreotate therapy with priming
Affected function | z | p | Targets from transcriptional data | |
|---|---|---|---|---|
1 day | ||||
► | Hyperpolarization | – | 1.7 × 10− 4 | ↑SGK, ↓SCN9A |
G2 phase arrest in cancer | – | 3.3 × 10− 4 | ↑SGK, ↑CDKN1A | |
Metabolism of D-glucose | – | 1.6 × 10− 3 | ↑APOE, ↑APOD | |
Cell migration | – | 2.2 × 10−3 | ↑APOE, ↑CDKN1A | |
Cancer cell morphology | – | 2.2 × 10−3 | ↑CDKN1A, ↑GDF15 | |
3 days | ||||
G1 phase | 1.0 | 1.1 × 10−6 | ↑CEL, ↑APOE, ↑CCND3, ↑DDIT3, ↑GADD45A, ↑CDKN1A, ↑GDF15, ↓CDCA5, ↑BAX | |
Tumor cell proliferation | − 1.5 | 1.4 × 10−5 | ↑BEX2, ↓DLGAP5, ↓CTGF, ↑DDIT3, ↑SGK, ↑TNFRSF10B, ↑GDF15, ↑DDB2, ↑BAX, ↓PBK, ↑VCAN, ↓PARVB, ↓FDFT1, ↑CEL, ↓ALDH1A1, ↑CCND3, ↑GADD45A, ↑CDKN1A, ↓CDCA5 | |
Cell death in cancer | − 0.20 | 1.4 × 10−5 | ↑DDIT3, ↑GADD45A, ↑SGK, ↑BTG3, ↑TNFRSF10B, ↑CDKN1A, ↑GDF15, ↑BAX | |
Apoptosis in cancer | 2.0 | 2.2 × 10−5 | ↑CCND3, ↑DDIT3, ↑GADD45A, ↑SGK, ↑TNFRSF10B, ↑CDKN1A, ↑BAX, ↓PBK | |
Cancer cell viability | − 1.5 | 2.7 × 10−5 | ↑BEX2, ↓CTGF, ↓INSIG1, ↑CDKN1A, ↑GDF15, ↓PBK | |
7 days | ||||
Clustering of cancer cells | – | 1.5 × 10−5 | ↑CDH1, ↑CDKN1A | |
Metabolism of cholesterol | – | 2.8 × 10−5 | ↑CEL, ↑APOE, ↓LDLR, ↑ABCA1 | |
Invasion of tumor | – | 8.2 × 10−5 | ↑APOE, ↑CDH1, ↑CTSL, ↑GDF15 | |
Quantity of intercellular junctions | – | 9.0 × 10−5 | ↑CDH1, ↑GDF15 | |
Invasion of cells | 0.46 | 1.7 × 10−4 | ↑KISS1R, ↑CDH1, ↑CTSL, RHOB, ↑ACTA2, ↑TGFBI, ↑CDKN1A, ↑GDF15, ↓ENPP2, ↓AGR2, ↓BRINP3, ↑SERPINE2 | |
41 days | ||||
► | Quantity of Ca2+ | – | 2.2 × 10−4 | ↑IAPP, ↑GCGR, ↑CCK, ↓LGALS1 |
► | Tumor sphere formation | – | 6.0 × 10−4 | ↓SOX2, ↓CXCR7 |
Proliferation of cancer cells | − 1.2 | 1.3 × 10−3 | ↓SOX2, ↓ALDH1A1, ↓CXCR7, ↑PPP2R2C | |
► | Apoptosis of T lymphoblasts | – | 1.3 × 10− 3 | ↓LGALS1 |
► | Budding of mitochondria | – | 1.3 × 10−3 | ↓LGALS1 |